Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05036252 · ClinicalTrials.gov registry record
Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity
A clinical trial of Breast Cancer and HER2-positive Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- 23
- Enrollment target
- 1
- Study location
NCT05036252: Active study of Breast Cancer and HER2-positive Breast Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05036252 is a study of Breast Cancer and HER2-positive Breast Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05036252, a study of Breast Cancer and HER2-positive Breast Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see whether the results of this test can be used to predict how well participants' heart and lungs will work if they continue to receive this kind of treatment.
Primary Outcome
The primary purpose is to evaluate baseline VO2peak in patients with HER2-positive solid tumors and left ventricular systolic dysfunction
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Echocardiography
- DIAGNOSTIC_TEST Echocardiogram
- DIAGNOSTIC_TEST Cardiopulmonary Exercise Test
Study Locations (1)
New York
- Memorial Sloan - Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2021-08-27 |
| Est. Completion | 2026-08-27 |
What the registry record for NCT05036252 still lists
NCT05036252 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower).
The record links to 8 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Echocardiography is the first listed.
NCT05036252 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT05036252 about?
NCT05036252 is a clinical study titled "Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity". The purpose of this study is to find out how much oxygen is used during a cardiopulmonary exercise test (CPET) in women who have mild cardiotoxicity after standard treatment for HER2-positive breast cancer, and to see whether the results of this test can be used to predict how well participants' hea...
What is the current status of trial NCT05036252?
This trial is currently active not recruiting. The enrollment target is 23 participants. The study started on 2021-08-27. Estimated completion is 2026-08-27.
What conditions does trial NCT05036252 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I.
What interventions are being tested in trial NCT05036252?
The interventions under investigation include: Echocardiography (DIAGNOSTIC_TEST), Echocardiogram (DIAGNOSTIC_TEST), Cardiopulmonary Exercise Test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05036252?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05036252 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05036252's enrollment target sits among peer trials
23 1056th of 1224 higher than 163 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI